Entera Bio, Inc.

The oral proteins and peptides market is projected to grow to $2.86 billion by 2028 at a CAGR of 22.4%, driven by factors like rising chronic diseases, biotechnology investments, and non-invasive treatments. Key advancements include novel oral peptides, AI in drug discovery, and oral insulin formulations.

Entera Bio Ltd. (NASDAQ:ENTX) saw a 19.0% increase in short interest to 52,600 shares by November 15th. The company's stock opened at $1.64, with a 52-week range of $0.52 to $3.35. Institutional investors like Parkman Healthcare Partners LLC increased their holdings, while HC Wainwright maintained a 'buy' rating with a $10.00 price target. Entera Bio focuses on orally delivered peptide and protein therapeutics.

Entera Bio Ltd. (NASDAQ:ENTX) saw a 9.4% increase in short interest to 44,200 shares by October 31st. Hedge funds like Virtu Financial and Signature Estate & Investment Advisors increased their stakes. The stock traded down to $1.73 with a 52-week range of $0.52-$3.35. HC Wainwright maintained a 'buy' rating with a $10.00 target price.

Entera Bio reported Q3 2024 financial results, highlighting progress on EB613, the first oral PTH(1-34) tablet for osteoporosis, and its N-Tab™ platform. The company anticipates FDA's potential ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs in January 2025. Entera also presented new pharmacological data for EB613 at ASBMR 2024 and announced topline results for its oral oxyntomodulin tablet program with OPKO Health. Financial highlights include a net loss of $3.0 million and cash and cash equivalents of $6.9 million as of September 30, 2024.

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

Entera Bio and OPKO Health report positive PK/PD results for their oral oxyntomodulin tablet, showing significant systemic exposure and glucose reduction in animal models, supporting further development for obesity and metabolic disorders.